Generated by AI
Akebia Therapeutics Inc. is a biopharmaceutical company focused on developing and commercializing therapies for people living with kidney disease. Its current product portfolio centers on treatments for chronic kidney disease-related complications, including anemia management and phosphorus control, supported by a nephrology-focused commercial organization. The company’s marketed medicines are used in renal care settings and address medical needs across dialysis and non-dialysis patient populations. Akebia also maintains a development pipeline built around hypoxia-inducible factor biology, which underpins its research in kidney disease and related metabolic disorders. Headquartered in Cambridge, Massachusetts, Akebia Therapeutics Inc. serves as a specialized player in the renal therapeutics market, combining commercial products, development-stage assets, and collaboration-based programs to support treatment options in nephrology.
Website180 Third Avenue
Waltham, MA, 02451
United States
The latest articles about AKBA.
Patients on Vafseo® (vadadustat) increased to approximately 11,500 at the end of Q3 2026 representing an increase of approximately 140% from the end of Q3 2025 Q3 2026 Vafseo® (vadadustat) net product revenues of $14.8 million, impacted by customer inventory reduction and market dynamics as Vafseo's TDAPA expiration approaches Positive VOICE data demonstrating statistically significant evidence of improved safety outcomes for patients treated with vadadustat versus an ESA presented by U.S. Renal
Summary of Nov 18's posts. Generated by AI.
Summary of Nov 18's posts. Generated by AI.
Summary of Nov 16's posts. Generated by AI.
Summary of Oct 29's posts. Generated by AI.
Investors talking about AKBA also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.